Julie Delyon

List of Publications by Year in descending order

70 papers	1,411 citations	394421 19 h-index	377865 34 g-index
95 all docs	95 docs citations	95 times ranked	2374 citing authors

#	Article	IF	Citations
1	Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Annals of Oncology, 2013, 24, 1697-1703.	1.2	280
2	Hemophilia A Induced by Ipilimumab. New England Journal of Medicine, 2011, 365, 1747-1748.	27.0	93
3	Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy. European Journal of Cancer, 2021, 149, 153-164.	2.8	79
4	Survival After Fulminant Myocarditis Induced by Immune-Checkpoint Inhibitors. Annals of Internal Medicine, 2017, 167, 683.	3.9	60
5	STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network. Journal of Investigative Dermatology, 2018, 138, 58-67.	0.7	47
6	Atypical BRAF and NRAS Mutations in Mucosal Melanoma. Cancers, 2019, 11, 1133.	3.7	47
7	Turning tumors from cold to inflamed to improve immunotherapy response. Cancer Treatment Reviews, 2021, 101, 102227.	7.7	42
8	Low-dose methotrexate-induced skin toxicity: Keratinocyte dystrophy as a histologic marker. Journal of the American Academy of Dermatology, 2015, 73, 484-490.	1.2	39
9	PD-1 blockade with nivolumab in endemic Kaposi sarcoma. Annals of Oncology, 2018, 29, 1067-1069.	1.2	34
10	Transient pituitary ACTH-dependent Cushing syndrome caused by an immune checkpoint inhibitor combination. Melanoma Research, 2017, 27, 649-652.	1.2	33
11	Management of Kaposi sarcoma after solid organ transplantation: A European retrospective study. Journal of the American Academy of Dermatology, 2019, 81, 448-455.	1.2	31
12	Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors. Annals of the Rheumatic Diseases, 2019, 78, e82-e82.	0.9	30
13	Immune checkpoint inhibitor rechallenge in patients with immune-related myositis. Annals of the Rheumatic Diseases, 2019, 78, e129-e129.	0.9	30
14	Acquired generalized lipodystrophy under immune checkpoint inhibition. British Journal of Dermatology, 2020, 182, 477-480.	1.5	29
15	Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review. British Journal of Haematology, 2020, 189, 985-992.	2.5	27
16	PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma. Oncogene, 2017, 36, 3252-3262.	5.9	25
17	Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma. Current Opinion in Oncology, 2020, 32, 79-84.	2.4	25
18	The Ipilimumab Lesson in Melanoma: Achieving Long-Term Survival. Seminars in Oncology, 2015, 42, 387-401.	2.2	24

#	Article	IF	Citations
19	Nivolumab-induced alopecia areata: A reversible factor of good prognosis?. JAAD Case Reports, 2018, 4, 761-765.	0.8	21
20	Immune Checkpoint Inhibitors in Transplantationâ€"A Case Series and Comprehensive Review of Current Knowledge. Transplantation, 2021, 105, 67-78.	1.0	21
21	Management of immune-related adverse events resulting from immune checkpoint blockade. Expert Review of Anticancer Therapy, 2019, 19, 209-222.	2.4	20
22	PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study. Lancet Oncology, The, 2022, 23, 491-500.	10.7	20
23	Severe immune-related hepatitis induced by immune checkpoint inhibitors: Clinical features and management proposal. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101491.	1.5	18
24	Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study. Cancers, 2020, 12, 1666.	3.7	17
25	Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a national multicentre study. Rheumatology, 2021, 60, 5753-5764.	1.9	17
26	Efficacy and safety of brentuximab vedotin plus bendamustine in advancedâ€stage primary cutaneous Tâ€cell lymphomas. British Journal of Dermatology, 2019, 181, 1315-1317.	1.5	14
27	Rechallenge of immune checkpoint inhibitor after pembrolizumab-induced myasthenia gravis. European Journal of Cancer, 2019, 113, 72-74.	2.8	13
28	Severe gastrointestinal toxicity of MEK inhibitors. Melanoma Research, 2019, 29, 556-559.	1.2	13
29	Kaposi Sarcoma in HIV-positive Solid-Organ Transplant Recipients: A French Multicentric National Study and Literature Review. Transplantation, 2019, 103, e22-e28.	1.0	13
30	Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma. Translational Oncology, 2020, 13, 275-286.	3.7	13
31	Cochleovestibular toxicity induced by immune checkpoint inhibition: a case series. European Journal of Cancer, 2019, 117, 116-118.	2.8	12
32	A targeted genomic alteration analysis predicts survival of melanoma patients under BRAF inhibitors. Oncotarget, 2019, 10, 1669-1687.	1.8	12
33	Validation of a preclinical model for assessment of drug efficacy in melanoma. Oncotarget, 2016, 7, 13069-13081.	1.8	12
34	Standardized Patients or Conventional Lecture for Teaching Communication Skills to Undergraduate Medical Students: A Randomized Controlled Study. Psychiatry Investigation, 2020, 17, 299-305.	1.6	12
35	Deep cutaneous fungal infections in solid-organ transplant recipients. Journal of the American Academy of Dermatology, 2020, 83, 455-462.	1.2	11
36	<scp>EMMPRIN</scp> regulates Î²1 integrinâ€mediated adhesion through Kindlinâ€3 in human melanoma cells. Experimental Dermatology, 2015, 24, 443-448.	2.9	10

#	Article	IF	Citations
37	Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care. Cancers, 2019, 11, 1203.	3.7	10
38	Systemic Treatment Initiation in Classical and Endemic Kaposiâ€™s Sarcoma: Risk Factors and Global Multi-State Modelling in a Monocentric Cohort Study. Cancers, 2021, 13, 2519.	3.7	10
39	Enteritis without colitis in patients treated with immune checkpoint inhibitors: a tricky diagnosis. Melanoma Research, 2018, 28, 483-484.	1.2	9
40	Phase Iâ€“II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAFV600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism. Clinical Cancer Research, 2021, 27, 3876-3883.	7.0	8
41	Long-Term Outcome of Neoadjuvant Tyrosine Kinase Inhibitors Followed by Complete Surgery in Locally Advanced Dermatofibrosarcoma Protuberans. Cancers, 2021, 13, 2224.	3.7	8
42	IL-6 blockade in cancer patients treated with immune checkpoint blockade: A win-win strategy. Cancer Cell, 2022, 40, 450-451.	16.8	8
43	Recurrence of Immune-Mediated Colitis Upon Immune Checkpoint Inhibitor Resumption: Does Time Matter?. Journal of Clinical Oncology, 2019, 37, 3563-3564.	1.6	7
44	Usefulness of the â€˜twoâ€step methodâ€™ of digital followâ€up for earlyâ€stage melanoma detection in highâ€risk French patients: a retrospective 4â€year study. British Journal of Dermatology, 2019, 181, 415-416.	1.5	7
45	FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated Melanoma. Cancers, 2020, 12, 1062.	3.7	7
46	A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans. Journal of Investigative Dermatology, 2021, 141, 761-769.e2.	0.7	7
47	Specific lymph node involvement in scleromyxedema: a new diagnostic entity for hypermetabolic lymphadenopathy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 679-683.	2.8	6
48	Checkpoint inhibitor treatment induces an increase in HbA1c in nondiabetic patients. Melanoma Research, 2019, 29, 328-332.	1.2	6
49	Clinicopathologic and molecular characterization of melanomas mutated for CTNNB1 and MAPK. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 475-480.	2.8	6
50	Hypoxia and MITF regulate KIT oncogenic properties in melanocytes. Oncogene, 2016, 35, 5070-5077.	5.9	5
51	Impact of New Systemic Treatment and Radiotherapy in Melanoma Patients with Leptomeningeal Metastases. Cancers, 2020, 12, 2635.	3.7	5
52	Dabrafenib and trametinib exposure-efficacy and tolerance in metastatic melanoma patients: a pharmacokineticâ€“pharmacodynamic real-life study. Cancer Chemotherapy and Pharmacology, 2021, 88, 427-437.	2.3	5
53	18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors. Cancers, 2022, 14, 3190.	3.7	5
54	Letter to the Editor: Could Immunogenicity of Kaposi Sarcoma Be More Linked to Viral Antigens Than to the Tumor Mutational Burden?. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1418-1419.	4.9	4

#	Article	IF	Citations
55	A multicenter phase II study of pazopanib in patients with unresectable or recurrent dermatofibrosarcoma protuberans (DFSP).. Journal of Clinical Oncology, 2018, 36, 11557-11557.	1.6	4
56	Yield of FDG PET/CT for Defining the Extent of Disease in Patients with Kaposi Sarcoma. Cancers, 2022, 14, 2189.	3.7	4
57	Clinical significance of BRAF/NRAS concurrent mutations in a clinicâ€based metastatic melanoma cohort. British Journal of Dermatology, 2020, 182, 1281-1283.	1.5	3
58	Increased risk of brain metastases among patients with melanoma and PROM2 expression in metastatic lymph nodes. Clinical and Translational Medicine, 2020, 10, e198.	4.0	3
59	Phase I-II open label multicenter study of PD0332991 in BRAF^{V600mut} metastatic melanoma patients harboring CDKN2A loss and RB1 expression and treated with vemurafenib.. Journal of Clinical Oncology, 2019, 37, 9545-9545.	1.6	3
60	Long-lasting, irreversible and late-onset immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs): A real-world data analysis.. Journal of Clinical Oncology, 2020, 38, e15095-e15095.	1.6	3
61	Keratinocyte Dystrophy as a Marker of Lowâ€Dose Methotrexateâ€“Induced Skin Toxicity: Comment on the Clinical Image by MÅ¶nch et al. Arthritis and Rheumatology, 2016, 68, 1790-1791.	5.6	2
62	Refractory hypotension with fever revealing checkpoint inhibitor-induced hypophysitis. Melanoma Research, 2019, 29, 205-207.	1.2	2
63	A Melanoma-Tailored Next-Generation Sequencing Panel Coupled with a Comprehensive Analysis to Improve Routine Melanoma Genotyping. Targeted Oncology, 2020, 15, 759-771.	3.6	2
64	Managing immune checkpoint inhibition in transplant recipients. Lancet Oncology, The, 2022, 23, 969-971.	10.7	2
65	Clinical response to immune checkpoint inhibition in patients with advanced skin cancers receiving concurrent ruxolitinib therapy for haematological malignancy. British Journal of Dermatology, 2021, 184, 564-566.	1.5	1
66	A process mining approach to real-world advanced melanoma treatments.. Journal of Clinical Oncology, 2020, 38, e22040-e22040.	1.6	1
67	Malignant, benign conventional and regulatory T immune compartments in 36 patients treated with mogamulizumab for advanced CTCL. European Journal of Cancer, 2019, 119, S4-S5.	2.8	0
68	Long-term outcome of neoadjuvant tyrosine kinase inhibitors (TKI) in locally advanced dermatofibrosarcoma protuberans (DFSP). Annals of Oncology, 2019, 30, v698.	1.2	0
69	Outcome of pretransplant melanoma after solid organ transplantation: an observational study. Transplant International, 2021, 34, 2154-2165.	1.6	0
70	Effect of extracellular matrix metalloproteinase inducer emmprin on ÃŸ1 integrin-mediated adhesion through a new partner, the kindlin-3, in human melanoma cells.. Journal of Clinical Oncology, 2014, 32, e22011-e22011.	1.6	0